Corporate Profile

Corporate History

August
2007
Established Momotaro-Gene Inc. in Okayama City, Okayama Prefecture, for research and development of REIC, a cancer suppressor gene, licensing research results, and bridging for commercialization
November
2007
Acquired exclusive licenses of REIC basic patent and prostate cancer cell apoptosis inducer patent
December
2007
Acquired exclusive licenses of cancer therapeutic drug patents containing the partial fragment of REIC gene
August
2008
Angel tax system preliminary approval (Chugoku Bureau of Economy, Trade and Industry No. 1)
October
2008
Headquarters moved to Okayama Medical Innovation Center (OMIC) Incubation Facility
June
2009
Production of GMP adeno REIC started (NBC, UK)
August
2009
National Institute of Advanced Industrial Science and Technology (NEDO) Innovation Promotion Project (Clinical development of REIC expressing adenovirus formulation for malignant mesothelioma) adopted
November
2009
Concluded licensing agreement with EPS Co., Ltd. for manufacture, development and sales of REIC pharmaceuticals in China (with the change of organization of EPS Inc., now we conclude the same agreement with EPS(CHINA) Co., Ltd. which is a subsidiary of EPS.)
March
2010
Acceptance of IND (clinical trial) application to US Food and Drug Administration (FDA) (Phase I clinical trial for prostate cancer by adeno REIC formulation)
January
2011
Clinical research on REIC gene therapy for prostate cancer started at Okayama University Hospital
October
2011
Adopted for research achievement development project (A-STEP) by the National Institute of Science and Technology (JST)
May
2014
Phase I clinical trial started in the United States for early prostate cancer
July
2014
Signed license agreement with Kyorin Pharmaceutical for malignant mesothelioma in Japan
July
2014
Procured funds (150 million yen) from Japan Venture Capital Co., Ltd. and other 3 companies
September
2015
Started clinical trials for malignant mesothelioma by Kyorin Pharmaceutical
August
2016
Headquarters moved to Okayama Yanagi-machi Building (Okayama City Kita-ku)
March
2017
Procured large funds (1.12 billion yen including stock acquisition rights) from DCI Partners Co., Ltd. and other five companies
March
2017
Purchased REIC Basic patent and others 2 Patents from patent owners
February
2018
Doctor-led clinical phase I / Ib phase trial of REIC preparation for liver cancer started at Okayama University
September
2018
Acceptance of IND (clinical trial) application to US Food and Drug Administration (FDA) (Clinical trial of Ad-SEG-REIC with immunity checkpoint inhibitor incombination against malignant mesothelioma)